• br Structure of USP Schematic representation

  2019-11-29

  

  Structure of USP7 Schematic representation of the USP7 domain architecture is shown in Fig. 3B. USP7 is a 135 kDa protein that consists of seven domains, including the N-terminal TRAF-like (Tumor necrosis factor Receptor–Associated Factor) domain, followed by the catalytic core domain and the fiv

• br Conflicts of interest br Introduction G

  2019-11-29

  

  Conflicts of interest Introduction G protein-coupled receptors (GPCRs), form the largest human membrane protein family, with 800 members overall. Many druggable targets for treatment of common diseases involve GPCRs that mediate therapeutic effects of 34% of all marketed drugs (Hauser, Attwood

• G DH has gained interest because of its broad substrate

  2019-11-29

  

  G3DH has gained interest because of its broad substrate specificity and site-selective oxidation properties [9,10]. The conversion product, 3-ketoglycoside, possesses potential as a starting material for the chemical industry such as in polymer and surfactants because the keto group becomes a specif

• An additional difference in ACC between

  2019-11-29

  

  An additional difference in ACC-1 between H. contortus and C. elegans is the results from the oocyte expression experiments. Here we found that unlike Cel-ACC-1 that was reported to form a functional homomeric channel (Putrenko et al., 2005), Hco-ACC-1 does not. However, we have observed that in gen

• br Acknowledgements The authors thank Drs

  2019-11-29

  

  Acknowledgements The authors thank Drs. C. Klein, I. Canisso and A. Claes with assistance in obtaining tissues. Supported by the Albert G. Clay Endowment, University of Kentucky. Introduction Neoplastic cells often develop drug resistance during tumor progression or cancer treatment (Turner a

• The action of pt PGE as an EP receptor

  2019-11-29

  

  The action of 17-pt-PGE2 as an EP1 receptor agonist [34] was demonstrated in several experimental settings, including cancer, neurons, vascular system, kidney and was confirmed by application of EP1 receptor selective antagonists [35], [36], [37], [38], [39], [40], [41]. Receptor binding studies in

• For this reason downstream components of the inflammatory pa

  2019-11-29

  

  For this reason, downstream components of the inflammatory pathway have been investigated in the search for alternative targets. Targeting such downstream elements might result in safer and more tolerable analgesics. PGE mediates its effects through binding to four G-protein-coupled receptors (EP1-4

• br Significance Ubl post translational modifications are pot

  2019-11-29

  

  Significance Ubl post-translational modifications are potential targets for developing novel therapeutics for life-threatening diseases, such as c-Myc- and KRas-driven cancers that lack targeted therapy. However, only a few drugs are available to target these modifications. This lack of drugs hig

• Two GPCR subtypes of interest in the myocardium

  2019-11-29

  

  Two GPCR subtypes of interest in the myocardium are the endothelin receptor (ETR) and the α1-adrenergic receptor (α1-AR). Upon ligand binding, these receptors canonically activate the Gαq protein leading to activation of phospholipase C, hydrolysis of phosphatidylinositol 4,5-bisphosphate into diacy

• Therefore HNE is an attractive therapeutic target and the de

  2019-11-29

  

  Therefore, HNE is an attractive therapeutic target and the design of new HNE inhibitors is a demanding field that has been extensively investigated in order to provide inhibitors with new molecular architectures, including the potent oxo-β-lactam class [14]. In the present work, a coumarin-based oxo

• The DDRs have also been shown to be regulators of

  2019-11-29

  

  The DDRs have also been shown to be regulators of certain immunological functions. DDR1 is expressed in stimulated peripheral blood mononuclear TRAM 39 (Kamohara et al., 2001) and on activated T cells (Chetoui et al., 2011, Hachehouche et al., 2010, Kamohara et al., 2001). DDR1 can mediate cell mig

• 366 2 Various domains of the HSA molecule

  2019-11-28

  

  Various domains of the HSA molecule have also been used to make bioconjugates with increased stability, better targeting properties, and/or extended half-lives in blood. For example, domain I of HSA has been used in the preparation of antibody conjugates. This was achieved through the use of a cyclo

• epacadostat receptor We further correlated OPRK and OPRM met

  2019-11-28

  

  We further correlated OPRK1 and OPRM1 methylation levels with individual characteristics in Xinjiang Han and Uygur controls. Partial correlation analyses showed that OPRK1 methylation was positively correlated with age in Uygur male controls (r=0.72, p=0.001, adjusted by body mass index (BMI), gluco

• br COTSget based Architectures This section

  2019-11-28

  

  COTSget-based Architectures This section describes how our COTSget-based architectures are defined. We use a design inspired by MDE to build a Domain-Specific Language (DSL) of the architecture, as can be seen in the metamodel of Fig. 3. This metamodel defines the abstract syntax of our DSL and i

• br Discussion The present results demonstrate that high

  2019-11-28

  

  Discussion The present results demonstrate that high dose estrogen–progestogen OC treatment produced impaired glucose tolerance and glucose tolerance was preserved during low dose estrogen–progestogen, high or low dose progestogen-only OC use. The study also shows that impaired glucose tolerance

15051 records 953/1004 page Previous Next First page 上5页 951952953954955 下5页 Last page